| Sumario: | The article focuses on SPRINTR (Swedish PRecision medicine Initiative for Novel Treatments and Research), a national research infrastructure established to enhance precision medicine in prostate cancer through efficient recruitment and biomarker-driven clinical trials. SPRINTR integrates molecular profiling, clinical data, and patient consent into routine diagnostic workflows across Sweden, creating a study-ready population for multiple research purposes including diagnosis, prognosis, treatment prediction, quality of life, and health economics. The platform supports standardized biomarker analysis, centralized data management, and broad ethical approval, enabling scalable, nationwide participation and facilitating equitable patient access to clinical trials. SPRINTR aligns with national and international precision medicine initiatives to accelerate biomarker validation and improve outcomes for men with prostate cancer.
|
|---|